Legal & General Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-14,090
| Closed | -$48K | – | 3407 |
|
|
2018
Q3 | $48K | Sell |
14,090
-8,456
| -38% | -$30.5K | ﹤0.01% | 2796 |
|
|
2018
Q2 | $85K | Sell |
22,546
-2,034
| -8% | -$9.9K | ﹤0.01% | 2545 |
|
|
2018
Q1 | $101K | Sell |
24,580
-6,629
| -21% | -$30.9K | ﹤0.01% | 2478 |
|
|
2017
Q4 | $146K | Hold |
31,209
| – | – | ﹤0.01% | 2431 |
|
|
2017
Q3 | $221K | Buy |
31,209
+3,004
| +11% | +$21.6K | ﹤0.01% | 2315 |
|
|
2017
Q2 | $203K | Buy |
28,205
+2,220
| +9% | +$13.9K | ﹤0.01% | 2294 |
|
|
2017
Q1 | $161K | Buy |
25,985
+300
| +1% | +$1.64K | ﹤0.01% | 2331 |
|
|
2016
Q4 | $151K | Buy |
25,685
+2,632
| +11% | +$14.4K | ﹤0.01% | 2340 |
|
|
2016
Q3 | $121K | Sell |
23,053
-1,122
| -5% | -$6.05K | ﹤0.01% | 2164 |
|
|
2016
Q2 | $160K | Hold |
24,175
| – | – | ﹤0.01% | 1861 |
|
|
2016
Q1 | $113K | Sell |
24,175
-6
| -0% | -$24 | ﹤0.01% | 1980 |
|
|
2015
Q4 | $119K | Hold |
24,181
| – | – | ﹤0.01% | 1978 |
|
|
2015
Q3 | $86K | Buy |
24,181
+3,837
| +19% | +$25.7K | ﹤0.01% | 2135 |
|
|
2015
Q2 | $199K | Buy |
20,344
+4,135
| +26% | +$44.3K | ﹤0.01% | 1752 |
|
|
2015
Q1 | $207K | Buy |
16,209
+2,461
| +18% | +$31.6K | ﹤0.01% | 1668 |
|
|
2014
Q4 | $197K | Hold |
13,748
| – | – | ﹤0.01% | 1581 |
|
|
2014
Q3 | $187K | Buy |
+13,748
| New | +$210K | ﹤0.01% | 1541 |
|
Legal & General Group's KERX Position: Q4 2018 in Review
Legal & General Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2018, closing a stake of 14,090 shares — an estimated $48K sold.
Legal & General Group first reported a position in KERX in Q3 2014 and held it in 17 quarters. The position peaked at $221K in Q3 2017. 1 fund tracked by Wall St. Rank holds KERX as of Q4 2018.
- Legal & General Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2018 after selling out during the quarter.
- Legal & General Group sold 14,090 Keryx Biopharmaceuticals Inc shares in Q4 2018, an estimated $48K.
- Legal & General Group first reported a position in Keryx Biopharmaceuticals Inc in Q3 2014 and held it in 17 quarters.
- Legal & General Group's Keryx Biopharmaceuticals Inc position peaked at $221K in Q3 2017.
- 1 fund tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2018.
Based on Legal & General Group's 13F filing for Q4 2018, filed 15 Feb 2019.